

Beamtree Holdings Limited (ASX: BMT)  
ASX Announcement

Sydney, 28 August 2026

## **BMT FY26 Full-Year Investor Update**

### **Recurring revenue up 10%**

**Beamtree Holdings Limited** (“**Beamtree**” or “**the Company**”) (**ASX: BMT**) applies deep clinical, coding and data expertise combined with AI to help hospitals and pathology labs improve clinical quality, coding accuracy, and reimbursement outcomes. AI-enabled proprietary platforms are co-developed with customers and embedded in live workflows, delivering system-level impact rather than point solutions.

### **Strategic review**

During the strategic review we refined our product mix, reshaped our cost base, tightened our capital allocation, sharpened our focus on sales execution, and strengthened our executive leadership team. We also simplified the organisation and clarified accountabilities across the business. We believe this sets us up well to capture the opportunities we see in our products and markets.

Going forward, we are focusing our investment on the products with strongest customer resonance, margin potential and capacity for innovation, namely our market leading Diagnostics product (Rippledawn), our Coding solutions (PICQ and PICQ Audit, RISQ) and our Analytics platform. This year we are launching our Autonomous Coding Solutions (ACS) product and our Autonomous Data Entry (ADE) product with selected customers.

During the year, we determined to exit the Ability Roundtable and Wellness Roundtable, each of which sat at a distance from our core hospital customer base. We are also winding down the Ainsoff Deterioration Index — a process we are managing in careful consultation with affected customers.

These changes will allow us to focus our human and capital resources appropriately.

The most important organisational change was to welcome Gareth Pye as our new Chief Executive Officer. Gareth joins us after 18 years at TechnologyOne, one of Australia’s genuine enterprise software success stories, where he helped scale an ASX-listed business from its domestic base into one with a substantial overseas footprint. He has been a CFO, a strategy lead, and a product lead. He brings deep, hands-on experience in enterprise software go-to-market, in building product organisations that scale, and in engaging the investor community — exactly the combination Beamtree needs to commercialise its strategy at pace.

The Company also took the opportunity to reassess the carrying values of certain intangible assets prior to 30 June 2026. These have been written down by \$13.1m, with no cash impact as at 30 June 2026 to provide a more accurate carrying value and provide the future benefit of a normal

depreciation and amortisation charge going forward to be more reflective of ongoing investment into capitalised R&D.

Our new CEO, Gareth Pye, said: *"I am excited to join Beamtree at this inflection point as we focus on our core strengths and competitive advantages Combined with our customer focus I believe that Beamtree is well positioned to achieve sustainable growth."*

## **FY26 key financials**

- Total revenue of \$29.2m with 94% recurring
- Recurring Revenue grew by 10%
- Positive Operating Profit of \$0.4m
- Continued investment in products with \$3.7m capitalised during the year
- Liquidity of \$5.5m as at 30 June 2026 – cash of \$2.5m and undrawn facility of \$3.0m

**-ENDS-**

Authorised for release by a duly authorised sub-committee of the Board.

For further information, please email [investor@beamtree.com.au](mailto:investor@beamtree.com.au)

## **About Beamtree**

A leading provider of AI decision support and data insights solutions, Beamtree supports healthcare providers globally. They believe in creating a better future for health by turning data into insights and action through automation. They help solve real-world problems in healthcare by developing smart tools that aim to improve patient outcomes. Their solutions and services offer customers an unrivalled range of analytics across four key product segments:

- **Diagnostic Technology:** Enabling the effective delivery of diagnostic services as they underpin the future of health and personalised medicine.
- **Clinical Decision Support:** Combining human and artificial expertise together to enhance decisions that improve care, value and experience.
- **Coding Assistance and Data Quality:** Digitising and automating workflows with data, classification, coding & technical expertise to improve information standardisation, quality and timeliness.
- **Analytics and Knowledge Networks:** Combining data analytics solutions with peer-to-peer alliances that accelerate innovation and knowledge diffusion.